Three months ago, Brent Saunders fired a shot across the bow of the USS Big Pharma, pledging to limit Allergan’s annual price increase on its portfolio drugs to no more than single-digit percentage hikes each year. On Monday, the new US president of diabetes specialist Novo Nordisk took that pledge. And 2017 is shaping up as a potential turning point in the heated public argument over drug prices in the US.
“We recognize that people with diabetes are finding it harder to pay for their healthcare, including the medicines we make,” noted Jakob Riis, Novo’s US president, in a post. “As a company focused on improving the lives of people with diabetes, this is not acceptable.”
